ACAD
ACADIA Pharmaceuticals Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
9.68
PEG
0.13
P/B
3.08
P/S
3.55
EV/EBITDA
28.00
DCF Value
$-40.11
FCF Yield
2.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
91.7%
Operating Margin
9.8%
Net Margin
36.5%
ROE
41.9%
ROA
25.0%
ROIC
8.1%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $284.0M | $273.6M | $1.60 |
| FY 2025 | $1.07B | $391.0M | $2.29 |
| Q3 2025 | $278.6M | $71.8M | $0.42 |
| Q2 2025 | $264.6M | $26.7M | $0.16 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.83
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.